{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:51:57Z","timestamp":1790805117074,"version":"4.1.0"},"reference-count":140,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T00:00:00Z","timestamp":1601424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA219154"],"award-info":[{"award-number":["R01 CA219154"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014039","name":"DOD Prostate Cancer Research Program","doi-asserted-by":"publisher","award":["X81XWH-19-1-0227"],"award-info":[{"award-number":["X81XWH-19-1-0227"]}],"id":[{"id":"10.13039\/100014039","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Metastatic castration-resistant prostate cancer (mCRPC) is a challenging disease to treat, with poor outcomes for patients. One antitumor vaccine, sipuleucel-T, has been approved as a treatment for mCRPC. DNA vaccines are another form of immunotherapy under investigation. DNA immunizations elicit antigen-specific T cells that cause tumor cell lysis, which should translate to meaningful clinical responses. They are easily amenable to design alterations, scalable for large-scale manufacturing, and thermo-stable for easy transport and distribution. Hence, they offer advantages over other vaccine formulations. However, clinical trials with DNA vaccines as a monotherapy have shown only modest clinical effects against tumors. Standard therapies for CRPC including androgen-targeted therapies, radiation therapy and chemotherapy all have immunomodulatory effects, which combined with immunotherapies such as DNA vaccines, could potentially improve treatment. In addition, many investigational drugs are being developed which can augment antitumor immunity, and together with DNA vaccines can further enhance antitumor responses in preclinical models. We reviewed the literature available prior to July 2020 exploring the use of DNA vaccines in the treatment of prostate cancer. We also examined various approved and experimental therapies that could be combined with DNA vaccines to potentially improve their antitumor efficacy as treatments for mCRPC.<\/jats:p>","DOI":"10.3390\/cancers12102831","type":"journal-article","created":{"date-parts":[[2020,9,30]],"date-time":"2020-09-30T09:41:01Z","timestamp":1601458861000},"page":"2831","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Treatment Combinations with DNA Vaccines for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)"],"prefix":"10.3390","volume":"12","author":[{"given":"Melissa","family":"Gamat-Huber","sequence":"first","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53726, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghwan","family":"Jeon","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53726, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura E.","family":"Johnson","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53726, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jena E.","family":"Moseman","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53726, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha","family":"Muralidhar","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53726, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3646-4961","authenticated-orcid":false,"given":"Hemanth K.","family":"Potluri","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53726, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1957-1164","authenticated-orcid":false,"given":"Ichwaku","family":"Rastogi","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53726, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Wargowski","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53726, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2117-7003","authenticated-orcid":false,"given":"Christopher D.","family":"Zahm","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53726, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1471-6723","authenticated-orcid":false,"given":"Douglas G.","family":"McNeel","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center, University of Wisconsin-Madison, Madison, WI 53726, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase iii trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013pd-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (ca184-043): A multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase ii keynote-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s40425-018-0326-x","article-title":"Measuring multiple parameters of cd8+ tumor-infiltrating lymphocytes in human cancers by image analysis","volume":"6","author":"Steele","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/pros.22862","article-title":"Infiltration of cd8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer","volume":"74","author":"Ness","year":"2014","journal-title":"Prostate"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.euf.2017.05.013","article-title":"Pd-l1 expression and cd8(+) t-cell infiltrate are associated with clinical progression in patients with node-positive prostate cancer","volume":"5","author":"Petitprez","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3389\/fimmu.2019.00603","article-title":"The tumor immune contexture of prostate cancer","volume":"10","author":"Vitkin","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00262-019-02394-w","article-title":"Increased indoleamine 2,3-dioxygenase activity and expression in prostate cancer following targeted immunotherapy","volume":"68","author":"Zahm","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/978-3-030-32656-2_7","article-title":"Immunological complexity of the prostate cancer microenvironment influences the response to immunotherapy","volume":"1210","author":"Prokhnevska","year":"2019","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1200\/JCO.19.01701","article-title":"Phase ii trial of a DNA vaccine encoding prostatic acid phosphatase (ptvg-hp [mvi-816]) in patients with progressive, nonmetastatic, castration-sensitive prostate cancer","volume":"37","author":"McNeel","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/01.cji.0000165353.19171.41","article-title":"Immune monitoring in a phase 1 trial of a psa DNA vaccine in patients with hormone-refractory prostate cancer","volume":"28","author":"Miller","year":"2005","journal-title":"J. Immunother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000020281","article-title":"Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: A phase i\/ii clinical trial","volume":"38","author":"Mincheff","year":"2000","journal-title":"Eur. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/sj.bjc.6602019","article-title":"A phase i trial of DNA vaccination with a plasmid expressing prostate-specific antigen in patients with hormone-refractory prostate cancer","volume":"91","author":"Pavlenko","year":"2004","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3816\/CGC.2005.n.036","article-title":"A phase i study of a DNA vaccine targeting prostatic acid phosphatase in patients with stage d0 prostate cancer","volume":"4","author":"Zlotocha","year":"2005","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"907","DOI":"10.2217\/fon-2017-0531","article-title":"Sipuleucel-t for the treatment of prostate cancer: Novel insights and future directions","volume":"14","author":"Handy","year":"2018","journal-title":"Future Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-t immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase iii trial of immunologic therapy with sipuleucel-t (apc8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3670","DOI":"10.1002\/cncr.24429","article-title":"Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-t in advanced prostate cancer","volume":"115","author":"Higano","year":"2009","journal-title":"Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Fong, L., Carroll, P., Weinberg, V., Chan, S., Lewis, J., Corman, J., Amling, C.L., Stephenson, R.A., Simko, J., and Sheikh, N.A. (2014). Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-t for localized prostate cancer. J. Natl. Cancer Inst., 106.","DOI":"10.1093\/jnci\/dju268"},{"key":"ref_22","first-page":"2444","article-title":"Combination immunotherapy of primary prostate cancer in a transgenic mouse model using ctla-4 blockade","volume":"60","author":"Hurwitz","year":"2000","journal-title":"Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(12)70007-4","article-title":"Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: A phase 1 dose-escalation trial","volume":"13","author":"Versluis","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_24","unstructured":"Higano, C. (2009, January 26\u201328). A phase iii trial of gvax immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (crpc). Proceedings of the 2009 Genitourinary Cancer Symposium, American Society of Clinical Oncology (ASCO), Orlando, FL, USA."},{"key":"ref_25","unstructured":"Small, E. (2009, January 26\u201328). A phase iii trial of gvax immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (crpc). Proceedings of the 2009 Genitourinary Cancer Symposium, American Society of Clinical Oncology (ASCO), Orlando, FL, USA."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e192589","DOI":"10.1001\/jamanetworkopen.2019.2589","article-title":"Factors associated with use of sipuleucel-t to treat patients with advanced prostate cancer","volume":"2","author":"Caram","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.pharmthera.2017.02.016","article-title":"DNA vaccines for prostate cancer","volume":"174","author":"Zahm","year":"2017","journal-title":"Pharmacol. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13046-019-1154-7","article-title":"Cancer DNA vaccines: Current preclinical and clinical developments and future perspectives","volume":"38","author":"Lopes","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1600-065X.2010.00980.x","article-title":"DNA vaccines: An historical perspective and view to the future","volume":"239","author":"Liu","year":"2011","journal-title":"Immunol Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"174378","DOI":"10.1155\/2010\/174378","article-title":"DNA vaccines: Developing new strategies against cancer","volume":"2010","author":"Fioretti","year":"2010","journal-title":"J. Biomed. Biotechnol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1084\/jem.188.6.1075","article-title":"Predominant role for directly transfected dendritic cells in antigen presentation to cd8+ t cells after gene gun immunization","volume":"188","author":"Porgador","year":"1998","journal-title":"J. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1007\/BF03401683","article-title":"Priming of cytotoxic t lymphocytes by DNA vaccines: Requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes","volume":"3","author":"Fu","year":"1997","journal-title":"Mol. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0264-410X(97)00213-2","article-title":"DNA immunization can stimulate florid local inflammation, and the antiviral immunity induced varies depending on injection site","volume":"15","author":"Yokoyama","year":"1997","journal-title":"Vaccine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1016\/j.vaccine.2006.12.005","article-title":"West nile virus: Recent trends in diagnosis and vaccine development","volume":"25","author":"Dauphin","year":"2007","journal-title":"Vaccine"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.vetimm.2015.11.003","article-title":"Cancer immunology and canine malignant melanoma: A comparative review","volume":"169","author":"Atherton","year":"2016","journal-title":"Vet. Immunol Immunopathol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Carter, C., Houser, K.V., Yamshchikov, G.V., Bellamy, A.R., May, J., Enama, M.E., Sarwar, U., Larkin, B., Bailer, R.T., and Koup, R. (2019). Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0222178"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Elizaga, M.L., Li, S.S., Kochar, N.K., Wilson, G.J., Allen, M.A., Tieu, H.V.N., Frank, I., Sobieszczyk, M.E., Cohen, K.W., and Sanchez, B. (2018). Safety and tolerability of hiv-1 multiantigen pdna vaccine given with il-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus hiv gag vaccine in healthy volunteers in a randomized, controlled clinical trial. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0202753"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(17)33105-7","article-title":"Safety, tolerability, and immunogenicity of two zika virus DNA vaccine candidates in healthy adults: Randomised, open-label, phase 1 clinical trials","volume":"391","author":"Gaudinski","year":"2018","journal-title":"Lancet"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1016\/j.vaccine.2016.04.077","article-title":"A phase 1 clinical trial of a DNA vaccine for venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation","volume":"34","author":"Hannaman","year":"2016","journal-title":"Vaccine"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1405044","article-title":"A 9-valent hpv vaccine against infection and intraepithelial neoplasia in women","volume":"372","author":"Joura","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"6338","DOI":"10.1016\/j.vaccine.2008.09.026","article-title":"A sars DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase i clinical trial","volume":"26","author":"Martin","year":"2008","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"25586","DOI":"10.18632\/oncotarget.25387","article-title":"Concurrent, but not sequential, pd-1 blockade with a DNA vaccine elicits anti-tumor responses in patients with metastatic, castration-resistant prostate cancer","volume":"9","author":"McNeel","year":"2018","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1016\/S0140-6736(15)00239-1","article-title":"Safety, efficacy, and immunogenicity of vgx-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 e6 and e7 proteins for cervical intraepithelial neoplasia 2\/3: A randomised, double-blind, placebo-controlled phase 2b trial","volume":"386","author":"Trimble","year":"2015","journal-title":"Lancet"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Kyriakopoulos, C.E., Eickhoff, J., Ferrari, A.C., Schweizer, M.T., Wargowski, E., Olson, B.M., and McNeel, D.G. (2020). Multicenter phase 1 trial of a DNA vaccine encoding the androgen receptor ligand binding domain (ptvg-ar, mvi-118) in patients with metastatic prostate cancer. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-20-0945"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/CJI.0b013e3182280db1","article-title":"A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors","volume":"34","author":"Weber","year":"2011","journal-title":"J. Immunother."},{"key":"ref_46","first-page":"254","article-title":"DNA vaccines for prostate cancer","volume":"8","author":"McNeel","year":"2012","journal-title":"Curr. Cancer Ther. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1016\/j.vaccine.2013.06.063","article-title":"DNA vaccine coding for the rhesus prostate specific antigen delivered by intradermal electroporation in patients with relapsed prostate cancer","volume":"31","author":"Eriksson","year":"2013","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1016\/j.ymthe.2020.02.018","article-title":"Cd8(+) t cells impact rising psa in biochemically relapsed cancer patients using immunotherapy targeting tumor-associated antigens","volume":"28","author":"Shore","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1158\/1078-0432.CCR-08-2632","article-title":"Ny-eso-1 DNA vaccine induces t-cell responses that are suppressed by regulatory t cells","volume":"15","author":"Gnjatic","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1200\/JCO.2008.19.9968","article-title":"Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage d0 prostate cancer","volume":"27","author":"McNeel","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3692","DOI":"10.1158\/1078-0432.CCR-14-0169","article-title":"Real-time immune monitoring to guide plasmid DNA vaccination schedule targeting prostatic acid phosphatase in patients with castration-resistant prostate cancer","volume":"20","author":"McNeel","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-019-0516-1","article-title":"Flt pet\/ct imaging of metastatic prostate cancer patients treated with ptvg-hp DNA vaccine and pembrolizumab","volume":"7","author":"Scarpelli","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40425-018-0333-y","article-title":"Prime-boost vaccination targeting prostatic acid phosphatase (pap) in patients with metastatic castration-resistant prostate cancer (mcrpc) using sipuleucel-t and a DNA vaccine","volume":"6","author":"Wargowski","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_54","first-page":"295","article-title":"Prostatic acid phosphatase expression in human tissues","volume":"4","author":"Graddis","year":"2011","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0090-4295(98)00278-7","article-title":"Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases","volume":"52","author":"Sweat","year":"1998","journal-title":"Urology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1007\/s00262-012-1270-0","article-title":"DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency cd8(+) t-cell responses and increases psa doubling time","volume":"61","author":"Chudley","year":"2012","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1158\/2326-6066.CIR-16-0390","article-title":"Prostate cancer cells express more androgen receptor (ar) following androgen deprivation, improving recognition by ar-specific t cells","volume":"5","author":"Olson","year":"2017","journal-title":"Cancer Immunol. Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-017-0260-3","article-title":"Pretreatment antigen-specific immunity and regulation-association with subsequent immune response to anti-tumor DNA vaccination","volume":"5","author":"Johnson","year":"2017","journal-title":"J. Immunother. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1001\/archsurg.1941.01210140043004","article-title":"Studies on prostatic cancer: Ii. The effects of castration on advanced carcinoma of the prostate gland","volume":"43","author":"Huggins","year":"1941","journal-title":"Arch. Surg."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1210\/endo-129-5-2471","article-title":"Androgen deprivation induces phenotypic and functional changes in the thymus of adult male mice","volume":"129","author":"Olsen","year":"1991","journal-title":"Endocrinology"},{"key":"ref_61","first-page":"337","article-title":"Castration alters peripheral immune function in normal male mice","volume":"84","author":"Viselli","year":"1995","journal-title":"Immunology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6098","DOI":"10.4049\/jimmunol.173.10.6098","article-title":"Augmentation of t cell levels and responses induced by androgen deprivation","volume":"173","author":"Roden","year":"2004","journal-title":"J. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"14565","DOI":"10.1073\/pnas.251140998","article-title":"T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer","volume":"98","author":"Mercader","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/pros.22476","article-title":"T cells localized to the androgen-deprived prostate are th1 and th17 biased","volume":"72","author":"Morse","year":"2012","journal-title":"Prostate"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1158\/1078-0432.CCR-10-2804","article-title":"Androgen deprivation boosts prostatic infiltration of cytotoxic and regulatory t lymphocytes and has no effect on disease-free survival in prostate cancer patients","volume":"17","author":"Sorrentino","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1158\/1078-0432.CCR-16-1780","article-title":"Sequencing of sipuleucel-t and androgen deprivation therapy in men with hormone-sensitive biochemically recurrent prostate cancer: A phase ii randomized trial","volume":"23","author":"Antonarakis","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.ju.0000165159.33772.5b","article-title":"Antiandrogen, vaccine and combination therapy in patients with nonmetastatic hormone refractory prostate cancer","volume":"174","author":"Arlen","year":"2005","journal-title":"J. Urol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"4526","DOI":"10.1158\/1078-0432.CCR-07-5048","article-title":"Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy","volume":"14","author":"Madan","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Obradovic, A.Z., Dallos, M., Zahurak, M.L., Partin, A.W., Schaeffer, E.M., Ross, A.E., Allaf, M.E., Nirschl, T.R., Chapman, C.G., and O\u2019Neal, T. (2020). T-cell infiltration and adaptive treg resistance in response to androgen deprivation with or without vaccination in localized prostate cancer. Clin. Cancer Res.","DOI":"10.1158\/1078-0432.CCR-19-3372"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial","volume":"376","author":"Oudard","year":"2010","journal-title":"Lancet"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.2217\/fon.13.65","article-title":"Recent advances revolutionize treatment of metastatic prostate cancer","volume":"9","author":"Madan","year":"2013","journal-title":"Future Oncol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3536","DOI":"10.1158\/1078-0432.CCR-07-4025","article-title":"Combination of docetaxel and recombinant vaccine enhances t-cell responses and antitumor activity: Effects of docetaxel on immune enhancement","volume":"14","author":"Garnett","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-05-2059","article-title":"A randomized phase ii study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer","volume":"12","author":"Arlen","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1080\/21645515.2015.1062190","article-title":"Randomized phase ii trial of docetaxel with or without psa-tricom vaccine in patients with castrate-resistant metastatic prostate cancer: A trial of the ecog-acrin cancer research group (e1809)","volume":"11","author":"McNeel","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1634\/theoncologist.2011-0234","article-title":"Phase ii trial of neoadjuvant docetaxel and cg1940\/cg8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer","volume":"18","author":"Vuky","year":"2013","journal-title":"Oncologist"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1517\/14712598.7.12.1893","article-title":"Gvax: An allogeneic, whole-cell, gm-csf-secreting cellular immunotherapy for the treatment of prostate cancer","volume":"7","author":"Ward","year":"2007","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12149-016-1093-8","article-title":"Pharmacokinetics of single dose radium-223 dichloride (bay 88-8223) in japanese patients with castration-resistant prostate cancer and bone metastases","volume":"30","author":"Yoshida","year":"2016","journal-title":"Ann. Nucl. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[(177)lu]-psma-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (lupsma trial): A single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1073\/pnas.94.11.5750","article-title":"Radiation and stress-induced apoptosis: A role for fas\/fas ligand interactions","volume":"94","author":"Reap","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances mhc class i expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J. Exp. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"15618","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Alard","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semradonc.2014.07.005","article-title":"Radiotherapy and immunogenic cell death","volume":"25","author":"Golden","year":"2015","journal-title":"Semin. Radiat. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1667\/RR3031.1","article-title":"Cytokines in radiobiological responses: A review","volume":"178","author":"Schaue","year":"2012","journal-title":"Radiat. Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1182\/blood-2009-02-206870","article-title":"Therapeutic effects of ablative radiation on local tumor require cd8+ t cells: Changing strategies for cancer treatment","volume":"114","author":"Lee","year":"2009","journal-title":"Blood"},{"key":"ref_87","first-page":"6028","article-title":"Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer","volume":"59","author":"Chakravarty","year":"1999","journal-title":"Cancer Res."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1158\/1078-0432.728.11.2","article-title":"Immune-mediated inhibition of metastases after treatment with local radiation and ctla-4 blockade in a mouse model of breast cancer","volume":"11","author":"Demaria","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.cgt.7700398","article-title":"Local tumor irradiation augments the antitumor effect of cytokine-producing autologous cancer cell vaccines in a murine glioma model","volume":"9","author":"Lumniczky","year":"2002","journal-title":"Cancer Gene Ther."},{"key":"ref_90","first-page":"769","article-title":"Enhanced eradication of local and distant tumors by genetically produced interleukin-12 and radiation","volume":"15","author":"Seetharam","year":"1999","journal-title":"Int. J. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1002\/ijc.22837","article-title":"Human sodium iodide symporter gene adjunctive radiotherapy to enhance the preventive effect of hmuc1 DNA vaccine","volume":"121","author":"Jeon","year":"2007","journal-title":"Int. J. Cancer"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ymthe.2017.11.011","article-title":"Irradiation enhances abscopal anti-tumor effects of antigen-specific immunotherapy through regulating tumor microenvironment","volume":"26","author":"Chang","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.bj.2019.09.002","article-title":"Immune checkpoint inhibitors win the 2018 nobel prize","volume":"42","author":"Huang","year":"2019","journal-title":"Biomed. J."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2567.1999.00888.x","article-title":"Interaction of ctla-4 (cd152) with cd80 or cd86 inhibits human t-cell activation","volume":"98","author":"Vandenborre","year":"1999","journal-title":"Immunology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41391-017-0013-x","article-title":"Combining intratumoral treg depletion with androgen deprivation therapy (adt): Preclinical activity in the myc-cap model","volume":"21","author":"Shen","year":"2018","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1084\/jem.20130579","article-title":"Fc-dependent depletion of tumor-infiltrating regulatory t cells co-defines the efficacy of anti-ctla-4 therapy against melanoma","volume":"210","author":"Simpson","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hemonc.2013.09.005","article-title":"The immunoinhibitory b7-h1 molecule as a potential target in cancer: Killing many birds with one stone","volume":"7","author":"Afreen","year":"2014","journal-title":"Hematol. Oncol. Stem. Cell Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e17257","DOI":"10.1097\/MD.0000000000017257","article-title":"Immunohistochemistry of immune checkpoint markers pd-1 and pd-l1 in prostate cancer","volume":"98","author":"Sharma","year":"2019","journal-title":"Medicine"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1600-065X.2009.00767.x","article-title":"Pd-1 signaling in primary t cells","volume":"229","author":"Riley","year":"2009","journal-title":"Immunol. Rev."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"28561","DOI":"10.18632\/oncotarget.25564","article-title":"Ipilimumab plus nivolumab and DNA-repair defects in ar-v7-expressing metastatic prostate cancer","volume":"9","author":"Boudadi","year":"2018","journal-title":"Oncotarget"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/1479-5876-11-89","article-title":"Sequencing ctla-4 blockade with cell-based immunotherapy for prostate cancer","volume":"11","author":"Wada","year":"2013","journal-title":"J. Transl. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"15732","DOI":"10.1038\/s41598-018-33933-7","article-title":"Combination of immune checkpoint blockade with DNA cancer vaccine induces potent antitumor immunity against p815 mastocytoma","volume":"8","author":"Lopes","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Kos, S., Lopes, A., Preat, V., Cemazar, M., Lampreht Tratar, U., Ucakar, B., Vanvarenberg, K., Sersa, G., and Vandermeulen, G. (2019). Intradermal DNA vaccination combined with dual ctla-4 and pd-1 blockade provides robust tumor immunity in murine melanoma. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0217762"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.ymthe.2017.11.010","article-title":"Synergy of immune checkpoint blockade with a novel synthetic consensus DNA vaccine targeting tert","volume":"26","author":"Duperret","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1158\/2326-6066.CIR-14-0206","article-title":"Pd-1 or pd-l1 blockade restores antitumor efficacy following ssx2 epitope-modified DNA vaccine immunization","volume":"3","author":"Rekoske","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Takeda, K., and Akira, S. (2015). Toll-like receptors. Curr. Protoc. Immunol., 109.","DOI":"10.1002\/0471142735.im1412s109"},{"key":"ref_114","first-page":"67","article-title":"Innate immunity: Structure and function of tlrs","volume":"23","author":"Delneste","year":"2007","journal-title":"Med. Sci."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.imlet.2009.09.002","article-title":"Tlr-9 signaling and tcr stimulation co-regulate cd8(+) t cell-associated pd-1 expression","volume":"127","author":"Wong","year":"2009","journal-title":"Immunol. Lett."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Zahm, C.D., Colluru, V.T., McIlwain, S.J., Ong, I.M., and McNeel, D.G. (2018). Tlr stimulation during t-cell activation lowers pd-1 expression on cd8+ t cells. Cancer Immunol. Res.","DOI":"10.1158\/2326-6066.CIR-18-0243"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.4049\/jimmunol.1900065","article-title":"Tlr2 stimulation increases cellular metabolism in cd8(+) t cells and thereby enhances cd8(+) t cell activation, function, and antiviral activity","volume":"203","author":"Zhang","year":"2019","journal-title":"J. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2217\/imt.15.120","article-title":"In situ vaccination for the treatment of cancer","volume":"8","author":"Hammerich","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/mi.2012.83","article-title":"Intravaginal tlr agonists increase local vaccine-specific cd8 t cells and human papillomavirus-associated genital-tumor regression in mice","volume":"6","author":"Decrausaz","year":"2013","journal-title":"Mucosal Immunol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/CJI.0b013e31820d2a05","article-title":"Antitumor activity mediated by cpg: The route of administration is critical","volume":"34","author":"Lou","year":"2011","journal-title":"J. Immunother."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12929-016-0238-3","article-title":"Combination of the toll like receptor agonist and \u03b1-galactosylceramide as an efficient adjuvant for cancer vaccine","volume":"23","author":"Gableh","year":"2016","journal-title":"J. Biomed. Sci."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s00705-014-2024-4","article-title":"Comparing the effect of toll-like receptor agonist adjuvants on the efficiency of a DNA vaccine","volume":"159","author":"Sajadian","year":"2014","journal-title":"Arch. Virol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/nm934","article-title":"Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase","volume":"9","author":"Uyttenhove","year":"2003","journal-title":"Nat. Med."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Croitoru-Lamoury, J., Lamoury, F.M., Caristo, M., Suzuki, K., Walker, D., Takikawa, O., Taylor, R., and Brew, B.J. (2011). Interferon-gamma regulates the proliferation and differentiation of mesenchymal stem cells via activation of indoleamine 2,3 dioxygenase (ido). PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0014698"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3390\/vaccines3030703","article-title":"The role of indoleamine 2, 3-dioxygenase in immune suppression and autoimmunity","volume":"3","author":"Mbongue","year":"2015","journal-title":"Vaccines"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.3389\/fimmu.2019.01801","article-title":"Limitations and off-target effects of tryptophan-related ido inhibitors in cancer treatment","volume":"10","author":"Gunther","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor t cell immunotherapy targeting ctla-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J. Exp. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40425-019-0562-8","article-title":"Phase 1\/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma","volume":"7","author":"Gibney","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/S1470-2045(19)30274-8","article-title":"Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (echo-301\/keynote-252): A phase 3, randomised, double-blind study","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1002\/pros.21181","article-title":"Indoleamine 2,3-dioxygenase (ido) activity influence tumor growth in the tramp prostate cancer model","volume":"70","author":"Kallberg","year":"2010","journal-title":"Prostate"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1016\/j.ejca.2008.05.023","article-title":"High expression of indoleamine 2,3-dioxygenase gene in prostate cancer","volume":"44","author":"Wyler","year":"2008","journal-title":"Eur. J. Cancer"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.3389\/fimmu.2018.01051","article-title":"Expression of indoleamine 2,3-dioxygenase induced by ifn-gamma and tnf-alpha as potential biomarker of prostate cancer progression","volume":"9","author":"Banzola","year":"2018","journal-title":"Front. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.clinbiochem.2014.05.001","article-title":"Serum kynurenine\/tryptophan ratio is not a potential marker for detecting prostate cancer","volume":"47","author":"Burgers","year":"2014","journal-title":"Clin. Biochem."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1158\/1078-0432.CCR-08-1988","article-title":"A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase sirna","volume":"15","author":"Yen","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ymthe.2004.05.015","article-title":"Therapeutic her2\/neu DNA vaccine inhibits mouse tumor naturally overexpressing endogenous neu","volume":"10","author":"Lin","year":"2004","journal-title":"Mol. Ther."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/j.ccell.2018.05.009","article-title":"Non-conventional inhibitory cd4(+)foxp3(-)pd-1(hi) t cells as a biomarker of immune checkpoint blockade activity","volume":"33","author":"Zappasodi","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1038\/s41590-019-0441-y","article-title":"Pd-1 blockade in subprimed cd8 cells induces dysfunctional pd-1(+)cd38(hi) cells and anti-pd-1 resistance","volume":"20","author":"Verma","year":"2019","journal-title":"Nat. Immunol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Jafari, S., Molavi, O., Kahroba, H., Hejazi, M.S., Maleki-Dizaji, N., Barghi, S., Kiaie, S.H., and Jadidi-Niaragh, F. (2020). Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer. Cell Mol. Life Sci.","DOI":"10.1007\/s00018-020-03459-1"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1093\/annonc\/mdy232","article-title":"Pembrolizumab for advanced prostate adenocarcinoma: Findings of the keynote-028 study","volume":"29","author":"Hansen","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"De Guillebon, E., Dardenne, A., Saldmann, A., Seguier, S., Tran, T., Paolini, L., Lebbe, C., and Tartour, E. (2020). Beyond the concept of cold and hot tumors for the development of novel predictive biomarkers and the rational design of immunotherapy combination. Int. J. Cancer.","DOI":"10.1002\/ijc.32889"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/10\/2831\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:15:18Z","timestamp":1760177718000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/10\/2831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,30]]},"references-count":140,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["cancers12102831"],"URL":"https:\/\/doi.org\/10.3390\/cancers12102831","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,30]]}}}